Rocuronium
As of the edition of 20 October 2026, Rocuronium is a small molecule: marketed, first approved in 1994 (US); acts on CHRNA1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Zemuron
- First approved
- 17 March 1994 (US)
- Approvals on record
- 7 in 2 regions
- Holder of the most recent approval
- B. Braun Medical; 4 holders in all
- Registered trials
- 157, 4 stopped early
- Disease areas
- Nervous system; Lungs and airways; Digestive system; Urinary and reproductive; Pregnancy and women's health; Cancer
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA1 | Acetylcholine receptor subunit alpha | P02708 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 66 | 45 | 4 | 1 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 11 | 9 | 2 | 0 |
| Phase 3 | 22 | 19 | 0 | 0 |
| Phase 4 | 55 | 31 | 2 | 3 |
| All trials | 157 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Organon | Originator and Acquired holder | 1994 to now |
| Fresenius Kabi | Later holder | 2025 to now |
| B. Braun Medical | Acquired holder | 2026 to now |